You have read all your free articles, to continue reading subscribe to read the rest of this content.
Oncopeptides has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), for OPD5 - a second drug candidate based on the Peptide Drug Conjugate platform (PDC). Oncopeptides plans to initiate clinical development of OPD5 with an open-label phase 1, dAlready a subscriber Login You…
The Harvard Business Review (HBR) has selected Pascal Soriot among the Top 100 Best Performing CEOs in the world for 2019, and one of only three CEOs from a biopharmaceutical company. HBR's ranking is based on a CEO’s financial performance as well as environmental, social, and governance (ESG) Already a…
The Wisconsin Technology Innovation Initiative (Wi2) and Orion Corporation have announced a strategic collaboration in pursuit of new medicines for oncological diseases. Under the terms of the agreement, target proteins (modes of action) identified and initially validated at UW-Madison will be prAlready a subscriber Login You have read all your…
SynAct Pharma has announced that its share started trading on Nasdaq Stockholm’s main list July 12, 2022. “SynAct Pharma has worked hard with its pipeline to make it to where it is today. To be traded on the main market is an important landmark and a stamp of quality for…
